VYNE Therapeutics Stock Jumps 30% On Positive Clinical Data Of VYN201 Trial
Shares of VYNE Therapeutics Inc. (VYNE) are gaining over 30% on Wednesday morning after the company announces positive preclinical data for inhaled formulation of VYN201 in an in vivo model of idiopathic pulmonary fibrosis.
VYNE is currently trading at $4.1000, up $0.9700 or 30.9904%, on the Nasdaq, on a volume of 13 million shares, above average volume of 20 thousand. The stock opened its trading at $3.3500 after closing Tuesday’s trading at $3.1300. The stock has traded between $1.9980 and $9.9000 in the past 52-week period.
VYNE Therapeutics, a clinical-stage biopharmaceutical company developing treatment of immuno-inflammatory conditions, announced new preclinical data showing the positive effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis or IPF.
“The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory and anti-fibrotic response,” said David Domzalski, President and Chief Executive Officer of VYNE. “These data in IPF support our thesis that VYN201 has potential utility as a locally-administered therapy across a variety of immuno-inflammatory indications and further underscores the potential value of our InhiBETTM BET inhibitor platform.”
IPF is a chronic, life-threatening, fibrosing lung disease with few treatment options. Patients experience debilitating symptoms, including shortness of breath and difficulty performing daily activities.
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placebo.
Reduction in lung fibrosis from VYN201 treatment resulted in significant improvements in blood oxygen saturation and functional lung volume.
Source: Read Full Article